To determine whether INPP4B overexpressing ER+ breast cancer cells exhibit enhanced sensitivity to Wnt-targeted therapies, four small molecule Wnt inhibitors that target different Wnt pathway components and are clinically approved and/or undergoing clinical trials were evaluated. The gene discussed is ESR1; the disease is breast cancer.